Validation of a Salivary miRNA Diagnostic Test for Autism Spectrum Disorder

Status: Unknown
Location: See all (16) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

This study involves sample collection to identify biomarkers relating to Autism Spectrum Disorder(ASD) in the saliva of children who are between the ages of 18 months to 6 years and 11 months. Participants will at each timepoint have a non-invasive saliva swab collected and complete a brief demographic and medical history questionnaire as well. Children in the pediatric/provider setting who will receive a referral for an ASD diagnosis because they were determined to have a suspicion of developing ASD will be enrolled in the study. Children will also be enrolled in the specialist evaluation setting where they will receive a DSM-5 diagnosis. A subset of both enrollment cohorts will also be followed up with at a third time point in which their diagnosis will be confirmed, and information about any ongoing treatment will be gathered.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 7
Healthy Volunteers: f
View:

• 18 through 83 months old

• The study will include children at risk for ASD as defined by meeting one or more of the following criteria:

‣ flagged positive on a developmental screening tool (see below for assessment cut off scores)

⁃ the child has a biological sibling with ASD

⁃ Significant provider concern based on parent report noted in the child's medical chart at the time of the appointment.

⁃ Significant parental concern

Locations
United States
California
University of California - Irvine
RECRUITING
Santa Ana
Georgia
Marcus Autism Center/Emory University
RECRUITING
Atlanta
Illinois
RUSH University
NOT_YET_RECRUITING
Chicago
Massachusetts
University of Massachusetts Medical School
RECRUITING
Worcester
New York
University of Rochester
RECRUITING
Rochester
Quadrant Biosciences
ACTIVE_NOT_RECRUITING
Syracuse
SUNY Upstate Medical University
NOT_YET_RECRUITING
Syracuse
Ohio
Cincinnati Children's Hospital Medical Center
RECRUITING
Cincinnati
MetroHealth Medical Center
RECRUITING
Parma
Nationwide Children's Hospital
RECRUITING
Westerville
Pennsylvania
Children's Hospital of Philadelphia
RECRUITING
Philadelphia
Drexel University
RECRUITING
Philadelphia
South Carolina
Prisma Health-Upstate
RECRUITING
Greenville
Texas
Texas Children's Hospital/Baylor College of Medicine
RECRUITING
Houston
Virginia
University of Virginia
RECRUITING
Charlottesville
Washington
Seattle Children's Hospital
RECRUITING
Seattle
Contact Information
Primary
Andrew Brindle
abrindle@quadrantbiosciences.com
3153260760
Backup
Arianna Montefusco
arianna.montefusco@quadrantbiosciences.com
3153260760
Time Frame
Start Date: 2022-03-16
Completion Date: 2023-07
Participants
Target number of participants: 6604
Treatments
Autism Spectrum Disorder (ASD)
Non-ASD
Related Therapeutic Areas
Sponsors
Collaborators: MetroHealth Medical Center, University of Rochester, Nationwide Children's Hospital, Emory University, Seattle Children's Hospital, University of California, Irvine, Children's Hospital Medical Center, Cincinnati, Children's Hospital of Philadelphia, University of Pittsburgh, State University of New York - Upstate Medical University, University of Massachusetts, Worcester, Holland Bloorview Kids Rehabilitation Hospital, Rush University, Children's Hospital Los Angeles, Prisma Health-Upstate, Drexel University, University of Virginia
Leads: Quadrant Biosciences Inc.

This content was sourced from clinicaltrials.gov